Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LECTENZ BIO, INC.
- Proposal award date
- 2018-09-01
- Contract end date
- 2020-02-29
- UEI
- JTGCK219C6F4
- Solicitation number
- PA15-052
- Topic code
- 100
Research abstract
PROJECT SUMMARY
Glycans have several distinct properties that make their development as disease biomarkers appealingFirstlytheir location on cell surfaces makes them the first point of contact for cellular interactionsand thus
they are crucial in the control of normal metabolic processesand converselythey function as pathogen
adhesion receptorsSecondlyspecific glycan structures that are not presentor are in low amounts in normal
stateproliferate or alter their sequence in disease statesAndlastlychanges in glycosylation may be found
in many proteinsincluding those that are highly abundantThus changes in the normal levels of glycan
structuressuch as terminal sialic acidmay be markers of disease statesNew highly specific reagents are
required in order to overcome current limitations in the discovery and exploitation of disease related glycansUsing structurally guided genetic manipulationswe are converting the NanB sialidase from Spneumococcus
into a high specificity affinity reagent for the detection of all types of sialic acid modifications of glycopeptides
and glycoproteinsBecause such a protein has lectin like propertiesbut is derived from an enzymeit is called
a andquot Lectenz andquotA NanB Lectenzaddresses a key need in disease glycomarker detectionnamelya robust and
easy to produce reagent specific for detecting all types of sialylated glycansThis reagent could be employed
in an affinity matrix for sample enrichmentwhich in conjunction with existing MS based methods could provide
linkage informationGlycopeptide sample enrichment aids glycomic analyses by eliminating non glycosylated
peptideswhich would otherwise attenuate the signals from glycopeptides that have low ionization efficiencyGlycosylation site mapping is essential in fully characterizing and exploiting glycans as markers of specific
disease statesbut at presentno reagent exists that can detect sialylated glycansindependent of the type of
linkage associated with the sialic acidThusat presenta number of reagents with varying specificities and
affinities must be employed to capture or detect all forms of sialylated glycansLectenzoffer numerous advantages over plant lectinsthey are engineered to be high affinity and yet retain
the exquisite substrate specificity of the endogenous enzymethey may be efficiently producedand for human
homologues have the potential to be employed in vivo with low toxicityWhereas some aspects of Lectenzdevelopment parallel those of antibody evolutionLectenzhave the tremendous benefit of employing a protein
na ve template that has the desired specificity PROJECT NARRATIVE
Using structurally guided genetic manipulationswe are converting carbohydrate processing enzymes into a
high specificity affinity reagentscalled Lectenzfor the detection of disease related modifications of
glycopeptides and glycoproteinsHere we are developing a LectenzSia PSspecific for the enrichment of
biologically important glycans that contain all forms of sialic acidThe principle advantages of engineered
Lectenzover other reagentssuch as antibodies or lectinsis that they have exquisite substrate specificity that
is not context dependentthey may be evolved to have desirable binding kineticsand that they may be
efficiently produced as monomeric proteins
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
18 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $14,474,759. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards